Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Veracyte Inc
VCYT | US
33.37
USD-0.48
-1.42%
VCYT | US
About Veracyte Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
33.37
Open
33.03
High
33.91
Low
32.73
Veracyte Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome Inc. and changed its name to Veracyte Inc. in March 2008. Veracyte Inc. was incorporated in 2006 and is headquartered in South San Francisco California.
View LessVCYT | US
Risk
48.1
Sharpe
-0.04
Luna's Score
48/100
Recommendation
Hold
Luna says (VCYT | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
61.0%1 month
48.1%3 months
40.0%6 months
58.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
31.75
Price to book
2.34
Debt to equity
0.02
Debt to assets
0.02
Ent. to EBITDA
-26.62
Ent. to rev.
6.08
PEG
-
Other Fundamentals
EBITDA
32.18M
MarketCap
2.56B
MarketCap(USD)
2.56B
Div. yield
-
Op. margin
4.72
Erngs. growth
-
Rev. growth
26.70
Ret. on equity
-4.88
Short ratio
3.91
Short perc.
4.74
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
7.17
Range1M
7.17
Range3M
14.03
Volumes: Market Activity
Rel. volume
1.46
Price X volume
46.17M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -26.62 | - | Cheaper |
| Ent. to Revenue | 6.08 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.34 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 39.96 | - | Lower Risk |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 2.56B | - | Emerging |
